Proteomics study of Mycoplasma pneumoniae pneumonia reveals the Fc fragment of the IgG-binding protein as a serum biomarker and implicates potential therapeutic targets

Liu, Jinrong; Shen, Rongfang; Feng, Lin; Cheng, Shujun; Xiao, Ting; Zhao, Shunying

doi:10.1007/s11684-021-0840-y

Cited by 5 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the rate of MR MP was 100% in this study, macrolides were still used in most patients, because of their anti-inflammation and anti-remodeling properties ( Kang et al., 2016 ). Sirolimus may also reduce airway inflammation and remodeling ( Wang et al., 2020 ) and it might be a potential therapeutic drug ( Liu et al., 2021 ); therefore, we prescribed sirolimus for 1 month in the recovery stage of Case 5.…”

Section: Discussionmentioning

confidence: 99%

Clinical features and “early” corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia

Liu

Zhang

et al. 2023

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

BackgroundMany children with mycoplasma pneumoniae (MP) pneumonia (MPP) developed sequelae such as bronchiolitis/bronchitis obliterans (BO). Early corticosteroid therapy might prevent disease progression. This study aimed to use “early” corticosteroid and observe the treatment outcome in patients with MPP.MethodsPatients who had pulmonary infiltrations on chest imaging within 5 days of the disease course and were suspected of having MP infection on admission were enrolled. Among them, patients whose disease course was within 10 days on admission were ultimately enrolled. We analyzed their data including the clinical features, the starting time and dose of corticosteroid therapy, and the treatment outcome. According to chest imaging, we divided patients into two groups (Group A: bronchiolitis-associated lesions or ground-glass opacities; Group B: pulmonary segmental/lobar consolidation).ResultsA total of 210 patients with confirmed MPP were ultimately enrolled. There were 59 patients in Group A and 151 patients in Group B. Patients in Group A were more prone to have allergy histories, hypoxemia, wheezing sound, and wet rales on auscultation than those in Group B. Corticosteroid treatment was initiated between 5 and 10 days of disease onset in all patients and 6–7 days in most patients. Methylprednisolone was prescribed in all patients within 10 days of disease onset, and the highest prescribed dose was at least 2 mg/kg/day. In Group A, methylprednisolone >2 mg/kg/day was prescribed in 22 patients, and among them, 8 patients with diffuse bronchiolitis-associated lesions received high-dose methylprednisolone therapy. After 3 months, lung CT revealed slightly segmental ground-glass opacity in three patients. In Group B, methylprednisolone >2 mg/kg/day was prescribed in 76 patients, and among them, 20 patients with pulmonary lobar consolidation received high-dose methylprednisolone therapy. After 3 months, chest imaging revealed incomplete absorption of pulmonary lesions in seven patients. Among them, five patients with consolidation in more than one pulmonary lobe ultimately had slight BO.ConclusionIn hospitalized patients with MPP, particularly severe MPP, the ideal starting time of corticosteroid treatment might be 5–10 days, preferably 6–7 days, after disease onset. The initial dosage of corticosteroid therapy should be decided according to the severity of the disease. MPP patients with diffuse bronchiolitis-associated lesions/whole lobar consolidation on imaging might require high-dose corticosteroid therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical features and “early” corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia

Liu

Zhang

et al. 2023

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[25] As per the study of Liu Jinrong.et al, the serum biomarkers could be used to decide and chose appropriate antibiotics to treat the acute pneumonia. [26] According to the study by Fernandez JF., irrespective of etiology and stage, the serum markers were highly cost effective tool in managing the acute pneumonia. [27] So the high degree of acute inflammatory response along with elevated levels of serum acute biomarkers like hs-CRP, LDH, Ferritin, NLR and WBCs count plays a significant role in detecting the degree of damage caused to all organ tissues with multi organ dysfunction and deciding the type of medications in comparison with IL6 and CT chest.…”

Section: Discussionmentioning

confidence: 99%

The Acute Inflammatory Biomarkers - Are They Cost Effective and Real Time Early Predictors of Mortality in Acute Pneumonia? - A Prospective Observational Study

Krishnamurthy,

Roja,

Bharathi

2023

JMSH

View full text Add to dashboard Cite

Introduction: The CT chest and investigations like IL6 and TNFɑ are the most accurate blood biomarkers of inflammatory changes and can be used to stage the severity and outcome of acute pneumonia. . Getting all the above mentioned investigations in a financially poor patients is not always possible. There are not much studies to look for the association between early raise in serum acute inflammatory bio markers and the prediction of mortality in acute pneumonia. So this study is under taken to know the association between significant raise in serum acute inflammatory biomarkers like hs CRP, LDH, ferritin, NLR, WBCs count in predicting the mortality of acute pneumonia in comparison with the serum IL6,q-SOFA score and CT chest severity score. Materials & Method: All patients underwent standardized workup, including complete blood count, blood biochemistry, ferritin, hs-CRP, LDH,IL6,CT scan of chest ,q-SOFA score assessment and electrocardiogram. All the biochemical investigations were done on day 1 and day 5 of admission to the hospital. The patients were followed-up for the whole in hospital stay duration. Results: All the measured serum acute inflammatory bio markers, IL6, NLR, WBCs count, q-SOFA score and chest CT severity score were significantly elevated in patients with death due to acute pneumonia than the survived ones. [p value-0.01] Conclusion: This study proves that, the early raise in serum acute inflammatory biomarkers have got real and cost effective predictive value and are non-inferior to total WBCs count, NLR,IL6, q- SOFA score and chest CT severity score in assessing the mortality of acute pneumonia. Keywords: Acute Pneumonia, Acute inflammatory bio markers, CT scan of Chest, IL6, NLR (Neutrophils to Lymphocytes ratio), q-SOFA score, WBCs count

show abstract

“…Thus, the degree of inflammation appears to be closely linked to the number and distribution of goblet cells. Moreover, the expression of FCGBP antigen in the serum of pneumonia patients decreased with the progression of the disease (45). Although the exact mechanism of FCGBP in the pathogenesis of Mycoplasma pneumoniae pneumonia is unknown, the role of this molecule in inflammation and progression cannot be ignored.…”

Section: Role Of Iggfc-binding Protein In Mucosal Defensesmentioning

confidence: 99%

Role of the mucin-like glycoprotein FCGBP in mucosal immunity and cancer

Niu

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

IgGFc-binding protein (FCGBP) is a mucin first detected in the intestinal epithelium. It plays an important role in innate mucosal epithelial defense, tumor metastasis, and tumor immunity. FCGBP forms disulfide-linked heterodimers with mucin-2 and members of the trefoil factor family. These formed complexes inhibit bacterial attachment to mucosal surfaces, affect the motility of pathogens, and support their clearance. Altered FCGBP expression levels may be important in the pathologic processes of Crohn’s disease and ulcerative colitis. FCGBP is also involved in regulating the infiltration of immune cells into tumor microenvironments. Thus, the molecule is a valuable marker of tumor prognosis. This review summarizes the functional relevance and role of FCGBP in immune responses and disease development, and highlights the potential role in diagnosis and predicting tumor prognosis.

show abstract

Proteomics study of Mycoplasma pneumoniae pneumonia reveals the Fc fragment of the IgG-binding protein as a serum biomarker and implicates potential therapeutic targets

Cited by 5 publications

References 42 publications

Clinical features and “early” corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia

Clinical features and “early” corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia

The Acute Inflammatory Biomarkers - Are They Cost Effective and Real Time Early Predictors of Mortality in Acute Pneumonia? - A Prospective Observational Study

Role of the mucin-like glycoprotein FCGBP in mucosal immunity and cancer

Contact Info

Product

Resources

About